11 completed, 5 unknown, 2 recruiting, 1 suspended. 11 Phase 2, 4 Not applicable, 4 Phase 1, 2 Phase 3, 1 Phase 4.
Follow D-serine: new trials by email Literature Review of D-serine trials Research Report on D-serine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression D-serine, Placebo - Parkinson s Disease, Parkinson Disease (PD) | Phase 2 | Recruiting | Haukeland University Hospital | 100 | 2026-01-20 | 2026-06-04 |
| Pharmacologic Augmentation of TMS for Depression With D-serine TMS, D-serine, Placebo - Depression | Phase 1 | Recruiting | Mclean Hospital | 60 | 2025-04-01 | 2026-05-15 |
| D-serine AudRem: R33 Phase D-serine, Placebo - Schizophrenia, Schizo Affective Disorder | Phase 1 / Phase 2 | Suspended | New York State Psychiatric Institute | 60 | 2022-12-01 | 2026-04-29 |
| The Effect of D-serine as add-on Therapy in Recent-onset Psychosis D-serine, Placebo - Psychotic Disorder | Not applicable | Terminated | Dragos Inta | 3 | 2021-11-25 | 2022-09-10 |
| D-serine Supplementation for Depression D-serine, Placebo - Major Depressive Disorder | Not applicable | Completed | André Schmidt | 44 | 2021-07-01 | 2024-05-10 |
| D-serine Augmentation of Neuroplasticity D-serine, Placebo - Schizophrenia, Schizo Affective Disorder | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 45 | 2019-03-13 | 2022-06-14 |
| A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers CTP-692, D-Serine - Healthy Volunteers | Phase 1 | Completed | Concert Pharmaceuticals | 13 | 2018-12-14 | 2019-03-15 |
| D-serine in Schizophrenia D-serine - Schizophrenia | Unknown | Herzog Hospital | 40 | 2018-09-01 | 2018-10-11 | |
| D-serine and Cognitive Remediation in Schizophrenia D-serine - Schizophrenia | Phase 2 | Completed | Nathan Kline Institute for Psychiatric Research | 8 | 2014-08-01 | 2020-10-08 |
| D-Serine for Cocaine Dependence Pilot D-serine, Cognitive Behavioral Therapy, Placebo - Cocaine Dependence | Phase 2 | Withdrawn | Theresa Winhusen | 2014-02-01 | 2014-02-06 | |
| D-Serine Treatment For Tardive Dyskinesia D-serine, Placebo - Schizophrenia and Schizoaffective Disorder, Tardive Dyskinesia | Not applicable | Unknown | Herzog Hospital | 16 | 2013-01-01 | 2018-10-11 |
| N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia D-serine, placebo, Sensory Based remediation paradigm - Schizophrenia, Schizoaffective Disorder | Phase 2 | Unknown | Nathan Kline Institute for Psychiatric Research | 16 | 2012-03-01 | 2012-10-25 |
| High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia D-serine - Schizophrenia | Phase 2 | Unknown | Hadassah Medical Organization | 54 | 2011-11-01 | 2011-10-25 |
| Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission D-serine, Riluzole, Placebo - Tourette Syndrome | Phase 4 | Completed | Johns Hopkins University | 39 | 2009-11-01 | 2018-01-30 |
| D-serine for the Schizophrenia Prodrome D-serine, Placebo - Schizophrenia Prodrome | Phase 2 | Completed | Nathan Kline Institute for Psychiatric Research | 44 | 2009-03-01 | 2017-08-14 |
| D-serine Monotherapy for Schizophrenia D-serine, Olanzapine - Schizophrenia | Phase 2 | Completed | Herzog Hospital | 18 | 2009-01-01 | 2013-12-10 |
| Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans D-serine, Placebo - Healthy | Not applicable | Completed | Herzog Hospital | 35 | 2007-04-01 | 2014-11-19 |
| Safety and Effectiveness of D-serine in Schizophrenia D-serine - Schizophrenia | Phase 2 | Completed | Nathan Kline Institute for Psychiatric Research | 55 | 2006-03-01 | 2020-10-05 |
| D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia D-serine, Cognitive retraining - Schizophrenia, Schizoaffective Disorder | Phase 3 | Completed | Yale University | 72 | 2005-02-01 | 2012-06-18 |
| Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia D-serine - Schizophrenia, Schizoaffective Disorder | Phase 2 | Unknown | Sheba Medical Center | 200 | 2004-10-01 | 2006-12-27 |
Showing 20 of 21. Sign in to see all of them.
Schizophrenia (13) · Psychotic Disorders (8) · Cocaine-Related Disorders (1) · Depression (1) · Depressive Disorder, Major (1) · Parkinson Disease (1) · Substance-Related Disorders (1) · Tardive Dyskinesia (1) · Tics (1) · Tourette Syndrome (1)
Herzog Hospital (4) · Nathan Kline Institute for Psychiatric Research (4) · New York State Psychiatric Institute (2) · Yale University (2) · André Schmidt (1) · Concert Pharmaceuticals (1) · Dragos Inta (1) · Hadassah Medical Organization (1) · Haukeland University Hospital (1) · Johns Hopkins University (1) · Mclean Hospital (1) · Sheba Medical Center (1) · Theresa Winhusen (1)
United States (10) · Israel (5) · Switzerland (2) · Australia (1) · India (1) · Norway (1)
Uriel Heresco-Levy, MD (3) · Joshua T Kantrowitz, MD (2) · Amit Lotan, MD (1) · Bernard Lerer, MD (1) · Daniel C Javitt, MD, PhD (1) · Daniel C. Javitt, MD, PhD (1) · Deepak C D'Souza, M.D. (1) · Deepak C. D'Souza, MD (1) · Emily McIntyre (1) · Harvey S Singer, MD (1) · Kerry Ressler, MD, PhD (1) · Mark Weiser, MD (1) · Uriel Heresco-Levy, M.D. (1)
PMID 22795211, PMID 25554623, PMID 26360284, PMID 27913408, PMID 28318835, PMID 36958998, PMID 37293030, PMID 37690312, PMID 40436209
2019 (1), R01DA022495 (1), R34MH085844 (1), U01MH074356 (1)